Chorostowska-Wynimko Joanna, Szpechcinski Adam
Laboratory of Molecular Diagnostics, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
J Thorac Oncol. 2007 Nov;2(11):1044-51. doi: 10.1097/JTO.0b013e318158eed4.
Lung cancer is the leading worldwide source of cancer-related death. It is acknowledged that prognosis and treatment outcomes in lung cancer might be improved by increasing the effectiveness of early-stage diagnosis. Several recently published studies have produced intriguing results regarding the detection of biomarkers in tumor samples, but also in easily accessible specimens such as sputum, plasma, and exhaled breath condensate. This review presents advances in genetic diagnostics of lung cancer, with particular reference to the clinical usefulness of individual biomarkers, specimens, and methods. The adequacy of their sensitivity and specificity for cancer screening and early detection is discussed in detail.
肺癌是全球癌症相关死亡的主要原因。人们认识到，通过提高早期诊断的有效性，肺癌的预后和治疗结果可能会得到改善。最近发表的几项研究在肿瘤样本中生物标志物的检测方面取得了有趣的结果，在痰液、血浆和呼出气冷凝液等易于获取的样本中也有相关发现。本综述介绍了肺癌基因诊断的进展，特别提及了个体生物标志物、样本和方法的临床实用性。详细讨论了它们在癌症筛查和早期检测中的敏感性和特异性的充分性。
